Pfizer's Melanoma Drug Gets New Lease On Phase III Life With Debiopharm Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of prior Phase III failure helped identify patients who will respond to the cancer immunotherapy tremelimumab.
You may also be interested in...
AACR Showcases Early Cancer Drugs, Early Use Of Biomarker Strategies
At the American Association for Cancer Research annual meeting in Chicago, data were presented on early-stage projects, some of them for the first time, as AACR displayed its growing enthusiasm for translational medicine.
Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.
Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.